loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tasquinimod

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tasquinimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Active Biotech inks global patent license agreement with Oncode Institute
    Active Biotech inks global patent license agreement with Oncode Institute

    11 Feb 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=145779&sid=2

    PHARMABIZ
    11 Feb 2022
    Share Share
    Active Biotech: Year End Report 2021
    Active Biotech: Year End Report 2021

    09 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/09/2382305/0/en/Active-Biotech-Year-End-Report-2021.html

    GLOBENEWSWIRE
    09 Feb 2022
    Share Share
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod

    07 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/07/2379644/0/en/Active-Biotech-announces-first-patient-dosed-in-the-combination-part-of-the-phase-Ib-IIa-study-of-tasquinimod-in-multiple-myeloma.html

    GLOBENEWSWIRE
    07 Feb 2022
    Share Share
    New preclinical data on tasquinimod will be presented at ASH
    New preclinical data on tasquinimod will be presented at ASH

    04 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/04/2327571/0/en/New-preclinical-data-on-tasquinimod-will-be-presented-at-the-annual-meeting-of-American-Society-of-Hematology-ASH.html

    GLOBENEWSWIRE
    04 Nov 2021
    Share Share
    Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating
    Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating

    02 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/02/2307449/0/en/Adaptive-Biotechnologies-Presents-New-Data-During-IDWeek-Demonstrating-the-Capability-of-Its-Immune-Medicine-Platform-to-Distinguish-Between-SARS-CoV-2-Infection-and-Vaccine-Respon.html

    GLOBENEWSWIRE
    02 Oct 2021
    Share Share
    Active Biotech announces first patient dosed in ph 1b/2a study of tasquinimod
    Active Biotech announces first patient dosed in ph 1b/2a study of tasquinimod

    03 Aug 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/08/03/2071486/0/en/Active-Biotech-announces-first-patient-dosed-in-phase-1b-2a-study-of-tasquinimod-use-in-treatment-of-multiple-myeloma.html

    GLOBENEWSWIRE
    03 Aug 2020
    Share Share